ストックスクリーナーアプリを入手
3.85
0.26%
0.01
アフターアワーズ：
3.85
前日終値:
$3.84
開ける：
$3.81
24時間の取引高:
1.00M
Relative Volume:
0.37
時価総額：
$293.74M
収益：
$80.00M
当期純損益:
$-76.12M
株価収益率:
-3.358
EPS:
-1.1465
ネットキャッシュフロー:
$-63.88M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+1.32%
6か月 パフォーマンス:
-53.89%
1年 パフォーマンス:
-44.04%
1日の値動き範囲:
$3.80
$3.855
1週間の範囲:
$3.796
$3.915
52週間の値動き範囲:
$2.83
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
名前
Fulcrum Therapeutics Inc
セクター
電話
617-651-8851
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.85 | 293.74M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | 開始されました | JP Morgan | Overweight |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-07-29 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | ダウングレード | Stifel | Buy → Hold |
| 2024-09-09 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-09-25 | 開始されました | Goldman | Neutral |
| 2023-08-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | アップグレード | Stifel | Hold → Buy |
| 2023-05-04 | ダウングレード | Goldman | Buy → Neutral |
| 2023-03-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2023-02-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 開始されました | Goldman | Buy |
| 2022-03-08 | 開始されました | Oppenheimer | Outperform |
| 2022-03-03 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-08-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2020-10-16 | 開始されました | Piper Sandler | Overweight |
| 2020-08-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-08-12 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Fulcrum Therapeutics Inc (FULC) 最新ニュース
Fulcrum (FULC) Quarter in Focus: The Available Earnings Metric Delivers a Beat in the Current Update; Market Response: Shares Finish 1.03% Higher on the DayEarnings Revision Report - vinanet.vn
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc.FULC - Business Wire
Slate Medicines to Merge With Fulcrum Therapeutics - Cooley
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations - FinancialContent
Truist Financial Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating - Moomoo
Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines - Sahm
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - Sahm
Latham Advises Frazier Life Sciences on Private Placement Financing With Fulcrum Slate Merger - Latham & Watkins LLP
Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com - Investing.com South Africa
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement with Key Financial Details - Kalkine Media
Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate - Stock Titan
Fulcrum Therapeutics to Merge With Slate Medicines in $245 Million Backed Migraine Play - finance.biggo.com
What's Going On With Fulcrum Therapeutics Stock Monday?Fulcrum Therapeutics (NASDAQ:FULC) - Benzinga
Slate Medicines goes public via Fulcrum merger to challenge PACAP migraine field - AllSci
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies - Yahoo Finance
Fulcrum Therapeutics shuts down, reverse-merges with N.C. biotech Slate - The Business Journals
Kaplan Fox Investigates Fulcrum Therapeutics After Pociredir Discontinuation Triggers 51% Stock Plunge - kalkine.ca
Fulcrum Therapeutics Target of Unusually Large Options Trading (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics and Slate Medicines to merge, refocusing combined company on migraine pipeline - The Pharma Letter
Fulcrum Therapeutics stock rises on Slate Medicines merger deal By Investing.com - Investing.com Australia
Fulcrum Therapeutics stock rises on Slate Medicines merger deal - Investing.com
Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Possible Securities Law Violations - The National Law Review
Fulcrum to merge with Slate in all-stock deal after drug setback - Reuters
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal - MarketBeat
Transcript : Fulcrum Therapeutics, Inc., Slate Medicines, Inc.M&A Call - marketscreener.com
Fulcrum (NASDAQ: FULC) plans special cash payout in Slate merger - Stock Titan
Fulcrum Therapeutics to Merge With Slate Medicines in Stock Deal Backed by $245 Million Financing - TradingView
Fulcrum Therapeutics, Inc. and Slate Medicines Announce Merger Agreement Call Transcript - GuruFocus
Fulcrum Therapeutics, Slate Medicines to Combine in All-Stock Merger - marketscreener.com
Why is Fulcrum Therapeutics stock rallying today? - Investing.com
Why is Fulcrum Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Fulcrum Therapeutics to merge with Slate Medicines in $245M deal - Investing.com Nigeria
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies - The Manila Times
Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders? - Sahm
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
Therapeutics, Inc. (FULC) RA Capital group now reports 0.0% stake - Stock Titan
Therapeutics, Inc. (FULC) 8.22% stake disclosed by Nantahala Capital - Stock Titan
Fulcrum Therapeutics (FULC): Montanova and affiliates report 5.5% ownership stake - Stock Titan
Fulcrum Therapeutics (FULC) investor group reduces reported ownership to 0% - Stock Titan
Fulcrum Therapeutics Faces Securities Investigation After Pociredir Program Discontinued and Stock Falls 51% - kalkine.ca
Assenagon Asset Management S.A. Has $3.06 Million Position in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDA - The National Law Review
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - Barchart.com
Kaplan Fox Launches Securities Probe into Fulcrum Therapeutics Following 51% Stock Plunge After Pociredir Program Halt - Kalkine Media
Fulcrum Therapeutics Faces Securities Law Investigation After Pociredir Program Discontinuation Triggers 51% Stock Drop - kalkine.ca
Fulcrum Therapeutics stock plunges 51% after FD... - Pluang
Fulcrum Therapeutics Appoints Alan Musso as Principal Accounting Officer Amid Leadership Change - Kalkine Media
Form 8K Fulcrum Therapeutics Inc For: 10 August By Investing.com - Investing.com Australia
Fulcrum Therapeutics appoints Alan Musso as principal accounting officer By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics appoints Alan Musso as principal accounting officer - Investing.com
Fulcrum Therapeutics Inc (FULC) 財務データ
収益
当期純利益
現金流量
EPS
Fulcrum Therapeutics Inc (FULC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | 10% Owner |
Jul 17 '26 |
Buy |
3.52 |
50,945 |
179,326 |
7,080,945 |
| TANG KEVIN | 10% Owner |
Jul 14 '26 |
Buy |
3.57 |
129,603 |
462,906 |
6,805,952 |
| TANG KEVIN | 10% Owner |
Jul 15 '26 |
Buy |
3.56 |
107,377 |
382,262 |
6,913,329 |
| TANG KEVIN | 10% Owner |
Jul 13 '26 |
Buy |
3.54 |
12,966 |
45,900 |
6,676,349 |
| Ezekowitz Alan | Director |
Jun 26 '26 |
Sale |
3.65 |
18,000 |
65,614 |
10,927 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):